ACDN-01 pediatric STELLAR dosing
Ascidian completed adult dose escalation in May 2026 and expanded STELLAR to participants aged 12 and older. ACDN-01 is a subretinal RNA exon editor for Stargardt disease and ABCA4 retinopathies.
What matters
Track what the company has actually announced, the study or asset involved, and the evidence needed to confirm the milestone.
- The company said pediatric enrollment was open; verify whether dosing is already public before activating this candidate.
- Research candidate, not a live market, clinical probability, company equity or access to private shares.
Primary evidence
Pediatric expansion announced May 2026; current dosing status unconfirmed
Company context
Company-authored LinkedIn About explicitly states Type: Privately Held and links ascidian-tx.com. Opened and checked October 31, 2026. This is an undated company self-report, not independent registry proof.
Potential outcome market
Will Ascidian confirm dosing of a participant under 18 with ACDN-01 in STELLAR by the market deadline?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.